Amgen Inc (AMGN)
284.26
-2.04
(-0.71%)
USD |
NASDAQ |
Mar 28, 16:00
284.00
-0.26
(-0.09%)
After-Hours: 20:00
Amgen Cash from Financing (TTM): 21.05B for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 21.05B |
September 30, 2023 | 17.24B |
June 30, 2023 | 20.84B |
March 31, 2023 | 20.99B |
December 31, 2022 | -4.037B |
September 30, 2022 | -9.546B |
June 30, 2022 | -8.286B |
March 31, 2022 | -9.846B |
December 31, 2021 | -8.271B |
September 30, 2021 | -5.303B |
June 30, 2021 | -9.949B |
March 31, 2021 | -6.552B |
December 31, 2020 | -4.867B |
September 30, 2020 | -3.206B |
June 30, 2020 | -4.267B |
March 31, 2020 | -11.03B |
December 31, 2019 | -15.77B |
September 30, 2019 | -17.41B |
June 30, 2019 | -17.13B |
March 31, 2019 | -15.78B |
December 31, 2018 | -22.49B |
September 30, 2018 | -21.06B |
June 30, 2018 | -19.58B |
March 31, 2018 | -16.18B |
December 31, 2017 | -6.594B |
Date | Value |
---|---|
September 30, 2017 | -6.582B |
June 30, 2017 | -4.893B |
March 31, 2017 | -5.937B |
December 31, 2016 | -2.599B |
September 30, 2016 | -1.399B |
June 30, 2016 | -3.439B |
March 31, 2016 | -1.147B |
December 31, 2015 | -3.771B |
September 30, 2015 | -6.011B |
June 30, 2015 | -5.066B |
March 31, 2015 | -4.176B |
December 31, 2014 | -3.274B |
September 30, 2014 | 3.695B |
June 30, 2014 | 6.995B |
March 31, 2014 | 5.816B |
December 31, 2013 | 2.726B |
September 30, 2013 | -2.428B |
June 30, 2013 | -3.791B |
March 31, 2013 | -1.801B |
December 31, 2012 | 419.00M |
September 30, 2012 | 3.457B |
June 30, 2012 | -186.00M |
March 31, 2012 | 457.00M |
December 31, 2011 | -674.00M |
September 30, 2011 | -3.546B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-17.41B
Minimum
Sep 2019
21.05B
Maximum
Dec 2023
-3.557B
Average
-7.412B
Median
Cash from Financing (TTM) Benchmarks
Gilead Sciences Inc | -5.125B |
Johnson & Johnson | -15.82B |
Eli Lilly and Co | 3.496B |
Merck & Co Inc | -4.81B |
Vertex Pharmaceuticals Inc | -562.20M |